Actinium Pharmaceuticals WKN: A2QA48 ISIN: US00507W2061 Forum: Aktien Thema: Hauptdiskussion
Hier nochmal die Zusammenfassung der Studienergebnisse: Primary endpoint met with 22% (=13 patients) vs control arm 0% (= 0 patients), FDA required 2x to control arm, Iomab-B achieved 22x, Primary endpoint met, 2x faster to get to transplant, 4x less sepsis (6.1% vs 28.6%), Less mucositis (15.2% vs 21.4%), Less acute gvhd (26.1% vs 35.7%), Not only more efficient, but also safer, Secondary endpoint, based of the Overall Survival chart (this is probability of being alive with Iomab-B vs chemo): 55% vs 43% at 6 months, 25% vs 14% at 1 year, 19 % vs 10% at 1.5 years, 14% vs 10 % at 2 years, at month 28.5 you have 0% probability of being alive if you were treated with chemo, 11% are alive with Iomab-B, 10% at 38 months with Iomab-B, 9% at 50 months (these patients are still alive/possibly curative)
|
|
Thema | ||
|---|---|---|---|
| 1 | Tilray Brands Hauptforum | +44,30 % | |
| 2 | Media and Games Invest | +2,11 % | |
| 3 | Beyond Meat Hauptdiskussion | -8,79 % | |
| 4 | Novo Nordisk | +3,05 % | |
| 5 | Vulcan Energy Resources Hauptdiskussion | +43,05 % | |
| 6 | NEL ohne Spam | -1,42 % | |
| 7 | BioNTech Hauptdiskussion | -1,17 % | |
| 8 | BORUSSIA DORTMUND Hauptdiskussion | +0,93 % | |
| 9 | VALNEVA SE Hauptdiskussion | -2,81 % | |
| 10 | PAG911 | +1,30 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | Tilray Brands Hauptforum | +44,30 % | |
| 2 | Media and Games Invest | +2,11 % | |
| 3 | Beyond Meat Hauptdiskussion | -8,79 % | |
| 4 | Novo Nordisk | +3,05 % | |
| 5 | Vulcan Energy Resources Hauptdiskussion | +43,05 % | |
| 6 | NEL ohne Spam | -1,42 % | |
| 7 | BioNTech Hauptdiskussion | -1,17 % | |
| 8 | BORUSSIA DORTMUND Hauptdiskussion | +0,93 % | |
| 9 | VALNEVA SE Hauptdiskussion | -2,81 % | |
| 10 | PAG911 | +1,30 % | Alle Diskussionen |